key: cord-309206-kq77whdx
authors: Yan, Victoria C.; Muller, Florian L.
title: Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
date: 2020-06-23
journal: ACS Med Chem Lett
DOI: 10.1021/acsmedchemlett.0c00316
sha: 
doc_id: 309206
cord_uid: kq77whdx

[Image: see text] While remdesivir has garnered much hope for its moderate anti-Covid-19 effects, its parent nucleoside, GS-441524, has been overlooked. Pharmacokinetic analysis of remdesivir evidences premature serum hydrolysis to GS-441524; GS-441524 is the predominant metabolite reaching the lungs. With its synthetic simplicity and in vivo efficacy in the veterinary setting, we contend that GS-441524 is superior to remdesivir for Covid-19 treatment.

W hile remdesivir has demonstrated efficacy against Covid-19, its broad translational applicability has been hampered by limited supply and distribution 1 due to the difficulty of its synthesis 2 and its obligatory intravenous (IV) administration requiring an inpatient setting. We recently described in a general audience publication 3 the advantages that the parent nucleoside of remdesivir, GS-441524, has over remdesivir itself for the treatment of Covid-19. Fundamentally, our investigation into the metabolism of remdesivir evidences premature serum hydrolysis of its phosphate prodrug, followed by dephosphorylation. 4−6 As a result, the major metabolite circulating in the bloodstream is the parent nucleoside, GS-441524, even though remdesivir (monophosphate nucleotide prodrug) was the species initially administered. Accounting for this broader pharmacokinetic (PK) rationale, we herein provide a detailed analysis of the literature that supports the use of GS-441524 over remdesivir for the treatment of Covid- 19 .

The Phosphate Prodrug on Remdesivir Is Not Intended for Lung-Specific Delivery. Remdesivir is a structural analogue of adenosine monophosphate (AMP) that interferes with the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp). 7 The anionic phosphate moiety on remdesivir is masked by McGuigan prodrug moieties 8 (phenol and L-alaninate ethylbutyl ester) to enhance cell permeability. In principle, these prodrug moieties would be removed intracellularlyfirst by esterases (cathepsin A/carboxylesterase 1) and then by phosphoramidases (HINT1-3) 9 to release the monophosphorylated nucleotide. This would then be phosphorylated twice to give the active NTP 7,9 (Figure 1a ), which is substrate-competitive with ATP for incorporation by viral RdRp and inhibition of viral RNA synthesis. 7 The McGuigan phosphate prodrug was partly developed to overcome the perceived rate-limiting first phosphorylation step toward the active triphosphorylated species. Bioactivation of the prodrug first involves carboxylesterases (CES1) and cathepsin A (CTSA), followed by phosphoramidases (histidine triad nucleotide binding proteins; HINTs; Figure 1a ). 9−11 Protein expression data from the Human Protein Atlas show that these enzymes (CES1, CTSA, HINT1, 2, 3) all have high expression in the liver, with minimal expression in type II pneumocytes in the lung 12 ( Figure 2 ). For the HINT family of phosphoramidases, there is some slight variation in each isoform's tissue-specific expression (Figure 2b, c) ; however, all 3 isoforms show high expression in the GI tract, liver, and kidneys. From the pattern of bioactivation for McGuigan prodrugs, it follows that the most significant accumulation active NTP will be in cell types with high expression of CES1/ CTSA/HINT1-3, such as the liver. Preferential bioactivation of McGuigan prodrugs such as remdesivir could explain the grade 3/4 adverse events related to liver and kidney damage in Covid-19 patients treated with remdesivir. 13 Seeing that the enzymes involved in McGuigan prodrug hydrolysis are hardly expressed in the lungs undermines its utility in the context of a primarily respiratory disease such as Covid-19.

GS-441524 Is the Predominant Metabolite in the Bloodstream When Remdesivir Is Administered IV. Hydrolytic enzymes are ubiquitous in serum. 14 This is one physiological factor that, especially for prodrugs, 15 prevents direct extrapolation of bioactivation mechanisms observed in vitro to the in vivo setting. For example, esterases and phosphatases are abundantly present in serum across species. 16,17 Premature serum hydrolysis of the McGuigan prodrug on remdesivir is thus unsurprising (Figure 1b) . Multiple studies have demonstrated that the nucleoside, GS-441524, is the predominant species in serum after remdesivir is administered (Figure 3b , c). 4−6 All studies that have investigated the PK of remdesivir in nonhuman primates (NHP) have concluded that intact remdesivir exhibits a short plasma half-life of about 0.4 h in serum, with "persistence" of the downstream nucleoside, GS-441524 ( Figure 3c ). 4,6 IV injection of remdesivir in NHP results in GS-441524 being present in serum at concentrations 1000-fold higher than remdesivir throughout a 7-day treatment course 6 ( Figure 3b ). This recurring phenomenon can first be explained by the abundance of plasma esterases, as the phosphoramidases (HINT1) involved in removal of the L-alanine have a strictly intracellular presence (see Human Protein Atlas HINT1). Inadvertent biotransformation of remdesivir to GS-441524 can be explained by the following sequence: (1) esterase removal of the L-alaninate ester, (2) intramolecular cyclization, displacement of the phenolate, followed by reopening of the ring, (3) cleavage of the phosphate ester by serum phosphatases or nucleosidases (Figure 1b) . The proposed serum bioactivation mechanism accounts for the general substrate constraints for each class of enzyme. For instance, CES1 is named as one of the enzymes involved in McGuigan prodrug hydrolysis. However, this does not preclude other esterases from acting on its L-alaninate ester. A study conducted by Sheahan and colleagues specifically investigated the PK of remdesivir in carboxylesterase 1c deficient mice (Ces1c −/− ). 5 Even in this Ces1c −/− model, the half-life of remdesivir was still short (t 1/2 ∼ 25 min), supporting the notion that other esterases are capable of performing the initial hydrolysis reaction. Thus, the abundance of hydrolytic enzymes in serum explains the persistent, multispecies observation that GS-441524 is the predominant metabolite when remdesivir is administered. 4−6 For the fleeting duration of time that remdesivir is in the blood (prior to hydrolysis to GS-441524), the expression of bioactivating enzymes for McGuigan prodrugs suggests that the highest concentrations of NTP formation by remdesivirrather than GS-441524 would occur in cell types with high expression of CES1/ CTSA/HINT1. This largely favors the liver over the lungs (Figure 2 ). Differential expression of prodrug bioactivating enzymes likely explains the wide range of EC 50 values with remdesivir in vitro. 18−20 GS-441524 Is Exceptionally Effective and Well-Tolerated against Clinical Presentations of Feline Coronavirus. There are currently no studies that have compared the antiviral activities of remdesivir and GS-441524 in vivo, with most focusing exclusively on remdesivir. Where GS-441524 has been investigated in vivo is in the veterinary setting. 21−23 Cats infected with feline coronavirus (FCoV) present with a serious disease known as feline infectious peritonitis (FIP). While long considered fatal in its severe manifestations, 24 a study conducted by Pedersen and colleagues showed that GS-441524 is capable of treating cats suffering from FIP with a 96% cure rate. 21 Pedersen noted the "impressive" safety profile of GS-441524, with no systemic signs of toxicity observed when administered subcutaneously at 4 mg/kg. 21 In a more recent study, Pedersen and colleagues escalated the dose of GS-441524 (5−10 mg/kg) to treat neurological manifestations of FIP; this translates to about 350−700 mg in a 70 kg human, greatly exceeding the dose currently given to patients treated with remdesivir (200 mg loading, then 100 mg). 13, 25 Even at these higher doses, they found that GS-441524 treatment resulted in the long term resolution of neurological FIP with an excellent safety profile: minimal dose-related toxicities were observed. 23 GS-441524 Shows Comparable Efficacy in Cell-Based Models of Primary Human Lung and Cat Cells Infected with Coronavirus. In vitro potency comparisons between GS-441524 and remdesivir are ultimately moot in the context of respiratory diseases such as SARS-CoV-2, if GS-441524 is the predominant species that reaches the lungs. To better gauge the efficacy of GS-441524 against SARS-CoV-2, it is helpful to first compare EC 50 values between coronavirus infected human and cat cells, as the clinical efficacy of GS-441524 has already been well-established in cats. 21 GS-441524 has an EC 50 value of 0.78 μM in CRFK cells infected with FCoV ( Figure 3a) . 26 At the time of publication, a study by Agostini and colleagues is the only report that has compared the antiviral activities of GS-441524 and remdesivir in primary human airway epithelial (HAE) cells, the most clinically relevant in vitro model of the lung, infected with either SARS-CoV or MERS-CoV. 27 While the mean EC 50 value of remdesivir is lower for both SARS-CoV and MERS-CoV-infected cells, close inspection of the data reveals large standard deviations between the EC 50 values obtained from GS-441524 and remdesivir making these potency differences not statistically significant (Figure 3a) . 27 For instance, against SARS-CoV-infected HAE cells, GS-441524 has a reported EC 50 of 0.18 (±0.14) μM, which is comparable, if not lower, than that required to exert antiviral activity against FCoV-infected cells in vitro. Most significantly, the EC 50 concentration for GS-441524 against SARS-CoVinfected primary HAE cells is sustained in the plasma of NHP for nearly the entire duration of the single-dose, 24 h PK experiment conducted by Warren and colleagues (Figure 3c ). In contrast, the EC 50 concentration for remdesivir against SARS-CoV-infected primary HAE cells diminishes after ∼2 h. The dominance of GS-441524 over remdesivir in serum was even more pronounced in Williamson's 7-day PK study, in which GS-441524 was present in serum at concentrations 1,000-fold greater than remdesivir at every measured time point (Figure 3b ). 6 Coupled with the robust antiviral activity that GS-441524 has demonstrated against FIP, these data compel further investigations into the therapeutic and prophylactic utility of GS-441524 against SARS-CoV-2 in patients. 

SARS-CoV-2 is a respiratory virus that primarily affects the lungs. 12 While remdesivir has shown some efficacy in patients with advanced Covid-19, 13 its phosphate prodrug is fundamentally not designed for lung-specific delivery. Enzymes that activate the McGuigan prodrug are preferentially expressed in tissues such as the liver, which results in uneven distribution of active NTP formation via remdesivir that disfavors the lungs. Practically, the structural complexity of the McGuigan prodrug 28 adds unnecessary synthetic difficulty that hampers mass production and impedes distribution. 1 Above all else, premature hydrolysis of the McGuigan prodrug, followed by dephosphorylation in serum such that GS-441524 is the predominant metabolite 4,5,29 compels studies investigating its utility in patients with Covid-19. In contrast to the prodrug activating enzymes that activate remdesivir, bioactivation of GS-441524 relies on expression of the kinase responsible for initial phosphorylation (likely adenosine kinase, ADK). According to the Human Protein Atlas, ADK is moderately expressed across all tissues, suggesting that administration of GS-441524 would result in even distribution across tissues. The remarkable safety profile of GS-441524, indicated by selectivity indices in vitro (EC 50 /CC 50 ratio) 2, 19, 30 and by clinical observations in cats, 21−23 suggest that higher dosing and lung NTP loading could be achieved with GS-441524 without encountering serious adverse effects. GS-441524 is also a structurally simple molecule that is easier to synthesize compared to remdesivir, 2 which would ease mass production and distribution. Especially amidst the documented premature serum hydrolysis of remdesivir to GS-441524, 4, 5, 29 we see several advantages to using GS-441524 over remdesivir for patients with Covid-19. While GS-441524, is not included in the emergency use authorization of remdesivir, the exigence of the pandemic may allow ordinary regulatory hurdles to be overcome, especially as these two drugs yield the same active species. An investigational new drug (IND) waiver or an emergency IND could be filed. The FDA has previously made allowances for prodrugs and their corresponding active substances, as in the case of Lenflunomide/Teriflunomide. 

The US Government's Supply of Covid-19

Drug Remdesivir Runs out at the End of the Month. CNN

Adenine C -Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses

Gilead Should Ditch Remdesivir and Focus on Its Simpler and Safer Ancestor

Therapeutic Efficacy of the Small Molecule GS-5734 against Ebola Virus in Rhesus Monkeys

Broad-Spectrum Antiviral GS-5734 Inhibits Both Epidemic and Zoonotic Coronaviruses

Clinical Benefit of Remdesivir in Rhesus Macaques Infected with SARS-CoV-2

The Antiviral Compound Remdesivir Potently Inhibits RNA-Dependent RNA Polymerase from Middle East Respiratory Syndrome Coronavirus

The ProTide Prodrug Technology: Where Next?

Metabolism and Pharmacokinetics of the Anti-Hepatitis C Virus Nucleotide Prodrug GS-6620 Downloaded From

Adenosine Monophosphoramidase Activity of Hint and Hnt1 Supports Function of Kin28, Ccl1, and Tfb3

Phosphoramidate Pronucleotides: A Comparison of the Phosphoramidase Substrate Specificity of Human and Escherichia Coli Histidine Triad Nucleotide Binding Proteins

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19

Remdesivir for the Treatment of Covid-19  Preliminary Report

Section of Medicine with Section of Pathology-Serum Enzymes in Clinical Practice

Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology; VHCA

Origins of Serum Alkaline Phosphatase

Remdesivir Potently Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice

GS-5734 and Its Parent Nucleoside Analog Inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci. Rep. 2017

Lopinavir, Emetine, and Homoharringtonine Inhibit SARS-CoV-2 Replication in Vitro

Efficacy and Safety of the Nucleoside Analog GS-441524 for Treatment of Cats with Naturally Occurring Feline Infectious Peritoniti

The Nucleoside Analog GS-441524 Strongly Inhibits Feline Infectious Peritonitis (FIP) Virus in Tissue Culture and Experimental Cat Infection Studies

Antiviral Treatment Using the Adenosine Nucleoside Analogue GS −441524 in Cats with Clinically Diagnosed Neurological Feline Infectious Peritonitis

Feline Infectious Peritonitis. ABCD Guidelines on Prevention and Management

Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial

The Nucleoside Analog GS-441524 Strongly Inhibits Feline Infectiousperitonitis (FIP) Virus in Tissue Culture and Experimental Cat Infection Studies

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease Downloaded From

Scaling up Remdesivir amid the Coronavirus Crisis. C&EN

Clinical Benefit of Remdesivir in Rhesus Macaques Infected with SARS-CoV-2

Synthesis and Antiviral Activity of a Series of 1′-Substituted 4-Aza-7,9-Dideazaadenosine C-Nucleosides